Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
43/100
This bibliometric review examines the evolving landscape of artificial intelligence (AI) in neurodegenerative diseases research from 2000 to March 16, 2025, utilizing data from 1,402 publications (1,159 articles, 243 reviews) indexed in the Web of Science Core Collection.
Why it matters
This is a count of publications about artificial intelligence in neurodegenerative disease research, showing that output grew quickly after 2017 and that the United States and China produced the most papers. It reports no treatment, cure, or prevention effect for Alzheimer's disease.
-
With the introduction of the new causal amyloid targeting therapies, the role of biomarker-assisted diagnosis of Alzheimer disease (AD) has received a further boost.
Why it matters
This paper discusses the strengths and weaknesses of imaging and fluid biomarkers and proposes an integrated algorithm for selecting patients for amyloid-targeting therapies. It is a commentary on biomarker use and does not itself treat, cure, or prevent Alzheimer's disease.
-
During a median follow-up of 13.68 years, 4744 incident all-cause dementia (ACD) events (including 3013 Alzheimer's disease (AD) and 853 vascular dementia (VaD)) were recorded.
Why it matters
In this UK Biobank cohort, participants with older biological age were at increased risk of incident dementia, including Alzheimer's disease and vascular dementia, and had worse cognitive and brain structural measures. The study identifies biological age as a potential risk factor but does not test any treatment or prevention.
-
Predicting the transition from mild cognitive impairment (MCI) to Alzheimer's disease (AD) has important clinical significance for dementia prevention and improving patient prognosis.
Why it matters
This review describes how multimodal MRI combined with AI may help predict conversion from mild cognitive impairment to Alzheimer's disease. It is a review of prediction research and reports no treatment, cure, or prevention.
-
Lewy body-involving diseases (LBD) are commonly associated with Parkinson's disease (PD) featuring voluntary movement inhibition, due to dopaminergic neuron dysfunction in the substantia nigra.
Why it matters
This hypothesis proposes that chronic environmental insult exposure and senescence-like neuron accumulation contribute toward initiating and sustaining Lewy body diseases, with co-occurring Alzheimer's disease pathologies involved in dementia symptomology. The hypothesis is presented as a proposed explanation, not a confirmed mechanism or treatment.
-
We identified 34 epidemiological studies that met the inclusion criteria.
Why it matters
This review of 34 studies found mixed results on whether exposure to metals affects Alzheimer's disease and related dementias in older women. Some studies reported harmful links for copper, cadmium, arsenic, lead and manganese, and protective links for selenium, iron and zinc in blood, but others found no connection, so no clear preventive advice can be given yet.
-
Ambient air pollution interacts with SVI to influence ADRD mortality rates.
Why it matters
This cross-sectional study found a significant interaction between particulate matter air pollution and social vulnerability index on ADRD mortality, and associations between ADRD mortality and specific social vulnerability subdomains and built environment variables. The findings support a role for non-traditional environmental and social factors in ADRD mortality, but do not test any treatment, cure, or prevention.
-
Globally, 9.84 million cases of ADOD occurred in 2021, with 1.95 million ADOD-related deaths, causing 36.33 million DALYs.
Why it matters
This analysis of global data found that 9.84 million cases of Alzheimer's disease and other dementias occurred in 2021, with incidence, mortality, and DALYs all increasing from 1990 to 2021. High fasting plasma glucose was the main risk factor, and the burden from high BMI was increasing while the burden from smoking steadily decreased.
-
A 78-year-old man with moderate Alzheimer disease (AD) dementia was treated with nasal-foralumab, a fully human anti-CD3 monoclonal antibody, as part of a Food and Drug Administration expanded-access-program, based on previously demonstrated efficacy of anti-CD3 antibody in animal models. 18 F-PBR06-PET, utilizing a second-generation 18-kDa-translocator-protein ligand targeting microglia, showed diffuse reduction of radiotracer uptake throughout the brain, following 3 months of nasal-foralumab compared with baseline.
Why it matters
A single 78-year-old man with moderate Alzheimer's dementia received nasal foralumab under an expanded-access programme, and PET imaging showed reduced microglial activation after three months. This is a single-patient, preliminary observation, so it cannot establish whether the treatment affects the course of Alzheimer's disease.
-
Through analytical validation, this assay demonstrated robust performance across multiple lots, operators, and instruments and could be used as a tool for diagnosing AD.
Why it matters
This paper reports the analytical validation of a blood test for P-tau217, including precision, stability, and an initial clinical assessment against brain amyloid. It is a test-development study and does not itself treat, cure, or prevent Alzheimer's disease.
-
Genetic variants increase the risk of neurocognitive disorders in later life, including vascular dementia (VaD) and Alzheimer’s disease (AD), but the precise relationships between genetic risk factors and underlying disease etiologies are not well understood.
Why it matters
This genetic study identified many genes associated with cognitive function, white matter hyperintensity, and Alzheimer's disease across European and African ancestry samples. It highlights biological pathways such as innate immunity and vascular dysfunction, but does not test any treatment or prevention.
-
Alzheimer's disease (AD) and vascular dementia (VaD) together contribute to almost 90 % of all dementia cases leading to major health challenges of our time with a substantial global socioeconomic burden.
Why it matters
This review compares Alzheimer's disease and vascular dementia and highlights shared mechanisms such as endothelial damage, blood-brain barrier breakdown and hypoperfusion. It discusses possible biomarkers and targets for future therapeutic strategies, but reports no tested treatment or cure.
-
Alzheimer’s disease (AD) is the most common cause of dementia, emphasizing the critical need for the development of biomarkers that facilitate accurate and objective assessment of disease progression for early detection and intervention to delay its onset.
Why it matters
By combining gene expression analysis with machine learning, this study identified UBE2N as a possible Alzheimer's disease biomarker, with reduced levels seen in the cortex and hippocampus of Tau P301S mice. It is early biomarker work and does not establish a treatment, cure or prevention.
-
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by memory loss and cognitive decline, with women being disproportionately affected in both prevalence and severity.
Why it matters
In a mouse model of Alzheimer's disease, both sexes showed mislocalization of GluN2B-containing NMDA receptors to extrasynaptic areas linked to memory dysfunction, with synaptic changes slightly less severe in females. The findings suggest targeting synaptic receptor trafficking as a possible therapeutic approach, but this is animal research only.
-
Key results included a 35% slowing of decline on the Integrated Alzheimer's Disease Rating Scale (iADRS) and a 36% slowing on the Clinical Dementia Rating-Sum of Boxes (CDR-SB).
Why it matters
This report states that donanemab showed a statistically significant slowing of cognitive and functional decline, with 35% slowing on one scale and 36% on another, and greater amyloid plaque clearance than aducanumab in a head-to-head comparison. It notes that further research is needed to validate long-term outcomes and refine dosing to minimize side effects.
-
Alzheimer disease (AD), the most common dementing syndrome in the United States, is currently established by the presence of amyloid-β and tau protein biomarkers in the setting of clinical cognitive impairment.
Why it matters
This review summarizes the current state of Alzheimer's disease genetics, including familial autosomal dominant genes, risk variants such as APOE ε4, and possible protective factors. It is an overview of genetic risk and does not test any treatment, cure, or prevention.
-
Alzheimer’s disease (AD) is a major neurodegenerative dementia, with its complex pathophysiology challenging current treatments.
Why it matters
This paper discusses hypotheses about Alzheimer's disease, including that amyloid-beta accumulation may be part of a broader process rather than the primary driver, and explores machine learning in drug discovery. It reports no tested treatment, cure, or prevention.
-
Alzheimer's disease (AD) is a complex, progressive, and irreversible neurodegenerative disorder marked by cognitive decline and memory loss.
Why it matters
This study combined cerebrospinal fluid biomarker information with hippocampal volumes to tell mild cognitive impairment apart from Alzheimer's disease using a hybrid machine learning model. It is a technical diagnostic approach and does not test any treatment, cure or prevention.
-
Copy number variation (CNV) of the amyloid-β precursor protein gene (APP) is a known cause of autosomal dominant Alzheimer disease (ADAD), but de novo genetic variants causing ADAD are rare.
Why it matters
This report describes a mother and daughter with a rare, complex rearrangement of chromosome 21 that tripled the APP gene and caused early-onset inherited Alzheimer's disease, with symptoms starting at age 58 in the mother and 34 in the daughter. It shows how detailed genome analysis can identify such structural changes, but it does not offer a treatment.
-
Data from 262 records (260 unique participants) were analyzed.
Why it matters
Machine learning models using routine visit data such as demographics, blood tests, MMSE subscores, and ApoE4 status were useful for classifying whether a person was amyloid-positive on PET scans. This is about improving screening and classification, not about treating, curing, or preventing Alzheimer's disease.
-
Apolipoprotein E ε4 (APOE ε4) bring the higher risk of Alzheimer' Disease (AD).
Why it matters
This study analyzed whether carrying the APOE ε4 risk gene changes how well cerebrospinal fluid biomarkers distinguish Alzheimer's disease, mild cognitive impairment and preclinical Alzheimer's from normal controls. It is about diagnostic test performance, not about treating, curing or preventing the disease.
-
As the leading cause of dementia worldwide, Alzheimer’s Disease (AD) has prompted significant interest in developing Deep Learning (DL) approaches for its classification.
Why it matters
Two deep learning models classified Alzheimer's disease from MRI data with satisfactory performance, and an explainability analysis showed they relied on brain regions relevant to Alzheimer's disease. This is a classification study and does not test treatment, cure, or prevention.
-
Our findings provide preliminary empirical support for a relationship between prodromal changes in retinal layers and a higher risk of AD or FTD, suggesting that macular OCT may serve as a non-invasive, sensitive biomarker of high-risk years before the onset of dementia.
Why it matters
In UK Biobank participants without dementia, reduced thickness of the ganglion cell-inner plexiform layer at baseline was associated with an increased risk of Alzheimer's disease, and thinner retinal pigment epithelium in one subfield was associated with elevated risk of frontotemporal dementia. The authors describe this as preliminary empirical support for a relationship between prodromal retinal changes and dementia risk, not a treatment, cure or prevention.
-
Finally, we showed that the MD-MRI-derived astrogliosis biomarker is the only MRI measure capable of predicting cognitive state.
Why it matters
This study found that a multidimensional MRI measure of cortical astrogliosis was associated with GFAP burden and could predict cognitive state, unlike conventional MRI parameters. It suggests a potential imaging biomarker for neuroinflammation, but it does not test any treatment or prevention for Alzheimer's disease.
-
Our results indicate that decline in semantic fluency is an early indicator of cognitive deficits in preclinical Alzheimer's disease.
Why it matters
This study found that amyloid-positive individuals with subjective cognitive decline declined faster on semantic fluency, and decline in fluency was associated with increased risk of clinical progression. Semantic fluency decline may be an early indicator of preclinical Alzheimer's disease, but no treatment is tested.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Decreased levels of circulating adiponectin in mild cognitive impairment and Alzheimer's disease
- Relation of cerebral vessel disease to Alzheimer's disease dementia and cognitive function in elderly people: a cross-sectional study
- Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease
- A mutation in APP protects against Alzheimer's disease and age-related cognitive decline
- Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration
- Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease
- Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy
- Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease
- Statins for the reduction of risk of Alzheimer's disease
- Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease